Approval · Notice of Compliance 11160 · 2010
VYVANSE: Notice of Compliance 11160
Issued March 19, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11160
- Date
- March 19, 2010
- Company
- Shire Canada IncLaval, QC, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New strengths: 20 mg, 40 mg and 60 mg
- Therapeutic class
- Central nervous system stimulant for attention deficit hyperactivity disorder
Products in this notice
Medicinal ingredients
- LISDEXAMFETAMINE DIMESYLATE 20 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 40 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 60 MG per CAP